Modified Nucleosides as Selective Modulators of Adenosine Receptors for Therapeutic Use

Modified Nucleosides: In Biochemistry, Biotechnology and Medicine

Volumn , Issue , 2008, Pages 433-449

  Jacobson, Kenneth A ^a   Joshi, Bhalchandra V ^a   Wang, Ben ^a   Klutz, Athena ^a   Kim, Yoonkyung ^b   Ivanov, Andrei A ^a   Melman, Artem ^a   Gao, Zhan Guo ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Ewha Womans University   (South Korea)

Author keywords

Adenylate cyclase; Agonist; Arthritis; Cancer; Glaucoma; Ischemia; Pain

Indexed keywords

EID: 80051527677     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623112.ch17     Document Type: Chapter

References (74)

1. Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K. N., Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
2. Schulte, G., Fredholm, B. B., Signalling from adenosine receptors to mitogenactivated protein kinases. Cellular Signalling 2003, 15, 813-827.
3. Jacobson, K. A., Gao, Z. G., Adenosine receptors as therapeutic targets. Nature Reviews Drug Discovery 2006, 5, 247-264.
4. Yan, L., Burbiel, J. C., Maass, A., Müller, C. E., Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opinion in Emerging Drugs 2003, 8, 537-576.
5. Cristalli, G., Lambertucci, C., Taffi, S., Vittori, S., Volpini, R., Medicinal chemistry of A2A adenosine receptor agonists.Curr. Top. Med. Chem. 2003, 3, 387-401.
6. Joshi, B. V., Jacobson, K. A., Purine derivatives as ligands for A3 adenosine receptors. Curr. Top. Med. Chem. 2005, 5, 1275-1295.
7. Sawynok, J., Adenosine and ATP receptors.Handbook Exp. Pharmacol. 2007, 177, 309-328.
8. Goldstein, R. N., Stambler, B. S., New antiarrhythmic drugs for prevention of atrial fibrillation. Prog. Cardiovasc. Dis. 2005, 48, 193-208.
9. Fredholm, B. B., Chen, J. F., Masino, S. A., Vaugeois, J. M., Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 385-412.
10. Huang, Z. L., Urade, Y., Hayaishi, O., Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr. Opin. Pharmacol. 2007, 7, 33-38.
11. Philipp, S., Yang, X. M., Cui, L., Davis, A. M., Downey, J. M., Cohen, M. V., Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2B receptor cascade. Cardiovasc. Res. 2006, 70, 308-314.
12. Jacobson, K. A., von Lubitz, D. K. J. E., Daly, J.W., Fredholm, B. B., Adenosine receptor ligands: differences with acute and chronic treatment. Trends Pharmacol. Sci. 1996, 17, 108-113.
13. Tracey, W. R., Magee, W. P., Oleynek, J. J., Hill, R. J., Smith, A. H., Flynn, D. M., Knight, D. R., Novel N6-substituted adenosine 50-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H2780-H2787.
14. Fishman, P., Bar-Yehuda, S., Madi, L., Adenosine, tumors, and immunity. In Adenosine Receptors, Therapeutic Aspects for Inflammatory and Immune Diseases (eds G. Haskó, B. N. Cronstein, C. Szabó), CRC Press, Boca Raton, 2006, pp. 299-312.
15. Madi, L., Cohn, S., Ochaion, A., Bar-Yehuda, S., Barer, F., Fishman, P., Over-expression of A3 adenosine receptor in PBMC of rheumatoid arthritis patients: Involvement of NF-kB in mediating receptor level. J. Rheumatol. 2007, 34, 20-26.
16. Yang, H., Avila, M. Y., Peterson-Yantorno, K., Coca-Prados, M., Stone, R. A., Jacobson, K. A., Civan, M. M., The crossspecies A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr. Eye Res. 2005, 30, 747-754.
17. Costanzi, S., Ivanov, A. A., Tikhonova, I. G., Jacobson, K. A., Structure and function of G protein-coupled receptors studied using sequence analysis, molecular modeling, and receptor engineering: Adenosine receptors. Frontiers Drug Design Discovery 2007, 3, 63-79.
18. Linden, J., Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 2005, 67, 1385-1387.
19. Holdgate, A., Foo, A., Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults. Cochrane Database Syst. Rev. 2006, 4, CD005154.
20. Peterman, C., Sanoski, C. A., Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol. Rev. 2005, 13, 315-321.
21. Giffin, N. J., Kowacs, F., Libri, V., Williams, P., Goadsby, P. J., Kaube, H., Effect of the adenosineA1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalagia 2003, 23, 287-292.
22. Song, Y., Wu, L., Shryock, J. C., Belardinelli, L., Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation 2002, 105, 118-123.
23. Cox, B. F., Clark, K. L., Perrone, M. H., Welzel, G. E., Greenland, B. D., Colussi, D. J., Merkel, L. A., Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J. Cardiovasc. Pharmacol. 1997, 29, 417-426.
24. Bayes, M., Rabasseda, X., Prous, J. R., Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 2005, 27, 331-372.
25. Glaxo Smith Kline, The study of GW493838, an adenosine A1 agonist, in peripheral neuropathic pain. http://clinicaltrials.gov/show/NCT00376454.
26. Zeraati, M., Mirnajafi-Zadeh, J., Fathollahi, Y., Namvar, S., Rezvani, M. E., Adenosine A1 and A2A receptors of hippocampal CA1 region have opposite effects on piriform cortex kindled seizures in rats. Seizure 2006, 15, 41-48.
27. Naganuma, M., Wiznerowicz, E. B., Lappas, C. M., Linden, J., Worthington, M. T., Ernst, P. B., Cutting edge: Critical role for A2A adenosine receptors in the T-cell-mediated regulation of colitis. J. Immunol. 2006, 177, 2765-2769.
28. Victor-Vega, C., Desai, A., Montesinos, M. C., Cronstein, B. N., Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel). Inflammation 2002, 26, 19-24.
29. Gao, Z. G., Mamedova, L., Chen, P., Jacobson, K. A., 2-Substituted adenosine derivatives: Affinity and efficacy at four subtypes of human adenosine receptors. Biochem. Pharmacol. 2004, 68, 1985-1993.
30. Rimondini, R., Ferre, S., Ogren, S. O., Fuxe, K., Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 1997, 17, 82-91.
31. Fuxe, K., Canals, M., Torvinen, M., et al., Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J. Neural Transm. 2007, 114, 49-75.
32. Filip, M., Frankowska, M., Zaniewska, M., Przegalinski, E., Muller, C. E., Agnati, L., Franco, R., Roberts, D. C. S., Fuxe, K., Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine.Brain Res. 2006, 1077, 67-80.
33. Hutchison, A. J., Webb, R. L., Oei, H. H., Ghai, G., Zimmerman, M. B., Williams, M., CGS21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 1989, 251, 47-55.
34. Hourani, S. M., Purinoceptors and platelet aggregation. J. Auton. Pharmacol. 1996, 16, 349-352.
35. Gordi, T., Frohna, P., Sun, H. L., Wolff, A., Belardinelli, L., Lieu, H., A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin. Pharmacokinet. 2006, 45, 1201-1212.
36. Barrett, R. J., Lamson, M. J., Johnson, J., Smith, W. B., Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J. Nucl. Cardiol. 2005, 12, 166-171.
37. Ohta, A., Sitkovsky, M., Role of G-proteincoupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414, 916-920.
38. Cerqueira, M. D., Advances in pharmacologic agents in imaging: newA2A receptor agonists. Curr. Cardiol. Rep. 2006, 8, 119-122.
39. Lappas, C. M., Sullivan, G. W., Linden, J., Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs 2005, 14, 797-806.
40. Lappas, C. M., Day, Y. J., Marshall, M. A., Engelhard, V. H., Linden, J., Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 2006, 203, 2639-2648.
41. van den Berge, M., Hylkema, M. N., Versluis, M., Postma, D. S., Role of adenosine receptors in the treatment of asthma and chronic obstructive pulmonary disease: recent developments. Drugs in R&D 2007, 8, 13-23.
42. Desai, A., Victor-Vega, C., Gadangi, S., Montesinos, M. C., Chu, C. C., Cronstein, B. N., Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol. Pharmacol. 2005, 67, 1406-1413.
43. Cavalcante, I. C., Castro, M. V., Barreto, A. R., Sullivan, G. W., Vale, M., Almeida, P. R., Linden, J., Rieger, J. M., Cunha, F. Q., Guerrant, R. L., Ribeiro, R. A., Brito, G. A., Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect. Immun. 2006, 74, 2606-2612.
44. Sun, C. X., Zhong, H., Mohsenin, A., Morschl, E., Chunn, J. L., Molina, J. G., Belardinelli, L., Zeng, D., Blackburn, M. R., Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. 2006, 116, 2173-2182.
45. Yang, D., Zhang, Y., Nguyen, H. G., Koupenova, M., Chauhan, A. K., Makitalo, M., Jones, M. R., Hilaire, C. St., Seldin, D. C., Toselli, P., Lamperti, E., Schreiber, B. M., Gavras, H., Wagner, D. D., Ravid, K., The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest. 2006, 116, 1913-1923.
46. Hua, X., Kovarova, M., Chason, K. D., Nguyen, M., Koller, B. H., Tilley, S. L., Enhanced mast cell activation in mice deficient in the A2B adenosine receptor. J. Exp. Med. 2007, 204, 117-128.
47. Feoktistov, I., Ryzhov, S., Zhong, H., Goldstein, A. E., Matafonov, A., Zeng, D., Biaggioni, I., Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 2004, 44, 649-654.
48. Kong, T., Westerman, K. A., Faigle, M., Eltzschig, H. K., Colgan, S. P., HIFdependent induction of adenosine A2B receptor in hypoxia. FASEB J. 2006, 20, 2242-2250.
49. Wakeno, M., Minamino, T., Seguchi, O., Okazaki, H., Tsukamoto, O., Okada, K., Hirata, A., Fujita, M., Asanuma, H., Kim, J., Komamura, K., Takashima, S., Mochizuki, N., Kitakaze, M., Long-term stimulation of adenosine A2B receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 2006, 114, 1923-1932.
50. Peyot, M. L., Gadeau, A. P., Dandre, F., Belloc, I., Dupuch, F., Desgranges, C., Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A(2b)-purinoceptor. Circ. Res. 2000, 86, 76-85.
51. Chiang, P. H., Wu, S. N., Tsai, E. M., Wu, C. C., Shen, M. R., Huang, C. H., Chiang, C. P., Adenosine modulation of neurotransmission in penile erection. Br. J. Clin. Pharmacol. 1994, 38, 357-362.
52. Gao, Z. G., Joshi, B. V., Klutz, A., Kim, S. K., Lee, H. W., Kim, H. O., Jeong, L. S., Jacobson, K. A., Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 50-ribofuran-uronamide moiety. Bioorg. Med. Chem. Lett. 2006, 16, 596-601.
53. Chen, Y., Corriden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinkernagel, A., Nizet, V., Insel, P. A., Junger, W. G., ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006, 314, 1792-1795.
54. Mabley, J., Soriano, F., Pacher, P., Haskó, G., Maårton, A., Wallace, R., Salzman, A., Szabó, C., The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-50-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. 2003, 466, 323-329.
55. Gurman, J., Yu, J. G., Suntres, Z., Bozarov, A., Cooke, H., Javed, N., Auer, H., Palatini, J., Hassanain, H. H., Cardounel, A. J., Javed, A., Grants, I., Wunderlich, J. E., Christofi, F. L., ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm. Bowel Dis. 2006, 12, 766-789.
56. Fedorova, I. M., Jacobson, M. A., Basile, A., Jacobson, K. A., Behavioral characterization of mice lacking the A3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cell. Mol. Neurobiol. 2003, 23, 431-447.
57. Matot, I., Weininger, C. F., Zeira, E., Galun, E., Joshi, B. V., Jacobson, K. A., A3 adenosine receptors and mitogenactivated protein kinases in lung injury following in vivo reperfusion. Critical Care 2006, 10, R65.
58. Xu, Z., Jang, Y., Mueller, R. A., Norfleet, E. A., IB-MECA and cardioprotection. Cardiovasc. Drug Rev. 2006, 24, 227-238.
59. Shneyvais, V., Mamedova, L., Zinman, T., Jacobson, K. A., Shainberg, A., Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J. Mol. Cell. Cardiol. 2001, 33, 1249-1261.
60. Chung, H., Jung, J. Y., Cho, S. D., Hong, K. A., Kim, H. J., Shin, D. H., Kim, H., Kim, H. O., Lee, H.W., Jeong, L. S., Kong, G., The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers. Mol. Cancer Ther. 2006, 5, 685-692.
61. Madi, L., Ochaion, A., Rath-Wolfson, L., Bar-Yehuda, S., Erlanger, A., Ohana, G., Harish, A., Merimski, O., Barer, F., Fishman, P., The A3 adenosine receptor is highly expressed in tumor vs. normal cells: Potential target for tumor growth inhibition. Clin. Cancer Res. 2004, 10, 4472-4479.
62. Baraldi, P. G., Preti, D., Tabrizi, M. A., Fruttarolo, F., Romagnoli, R., Carrion, M. D., Cara, L. C. L., Moorman, A. R., Varani, K., Borea, P. A., Synthesis and biological evaluation of novel 1-deoxy-1-6-((hetero)arylcarbonyl)hydrazino-9Hpurin-9-yl-N-ethyl-b-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. J. Med. Chem. 2007, 50, 374-380.
63. Adachi, H., Palaniappan, K. K., Ivanov, A. A., Bergman, N., Gao, Z. G., Jacobson, K. A., Structure-activity relationships of 2, N6,50-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J. Med. Chem. 2007, 50, 1810-1827.
64. Ueeda, M., Thompson, R. D., Arroyo, L. H., Olsson, R. A., 2-Aralkyloxyadenosines: Potent and selective agonists at the coronary artery A2 adenosine receptor. J. Med. Chem. 1991, 34, 1340-1344.
65. Zablocki, J. A., Wu, L., Shryock, J., Belardinelli, L., Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation. Curr. Topics Med. Chem. 2004, 4, 839-854.
66. Jeong, L. S., Lee, H. W., Jacobson, K. A., Kim, H. O., Shin, D.H., Lee, J. A., Gao, Z. G., Lu, C., Duong, H. T., Gunaga, P., Lee, S. K., Jin, D. Z., Chun, M.W., Moon, H. R., Structure-activity relationships of 2-chloro-N6-substituted-40-thioadenosine-50-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. J. Med. Chem. 2006, 49, 273-281.
67. Kim, S. K., Jacobson, K. A., Threedimensional quantitative structure-activity relationship of nucleosides acting at the A3 adenosine receptor: Analysis of binding and relative efficacy. J. Chem. Inf. Model. 2007, 47, 1225-1233.
68. Ge, Z. D., Peart, J. N., Kreckler, L. M., Wan, T. C., Jacobson, M. A., Gross, G. J., Auchampach, J. A., Cl-IB-MECA 2-chloro-N6-(3-iodobenzyl)adenosine-50-Nmethylcarboxamide reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. J. Pharmacol. Exp. Ther. 2006, 319, 1200-1210.
69. Philipp, S., Yang, X. M., Cui, L., Davis, A. M., Downey, J. M., Cohen, M. V., Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade.Cardiovasc. Res. 2006, 70, 308-314.
70. Albrecht, B., Krahn, T., Philipp, S., Rosentreter, U., Cohen, M., Downey, J., Selective A2b receptor activation mimics postconditioning in a rabbit infarct model. Circulation 2006, 114 (Suppl. II), II-14-II-15.
71. Solenkova, N. V., Solodushko, V., Cohen, M. V., Downey, J. M., Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am. J. Physiol. 2006, 290, H441-H449.
72. Eckle, T., Krahn, T., Grenz, A., Köhler, D., Mittelbronn, M., Ledent, C., Jacobson, M. A., Osswald, H., Thompson, L. F., Unertl, K., Eltzschig, H. K., Cardioprotection by ecto-50-nucleotidase (CD73) and A2B adenosine receptors. Circulation, 2007, 115, 1581-1590.
73. Baraldi, P. G., Preti, D., Tabrizi, M. A., Fruttarolo, F., Saponaro, G., Baraldi, S., Romagnoli, R., Moorman, A. R., Gessi, S., Varani, K., Borea, P. A., N6-(Hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl-(2-chloro)-50-N-ethylcarboxamidoadenosines: The first example of adenosine-related structures with potent agonist activity at the human A2B adenosine receptor. Bioorg. Med. Chem. 2007, 15, 2514-2527.
74. Jeong, L. S., Choe, S. A., Gunaga, P., Kim, H. O., Lee, H.W., Lee, S. K., Tosh, D., Patel, A., Palaniappan, K. K., Gao, Z. G., Jacobson, K. A., Moon, H. R. Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-40-thioadenosine derivatives without 40-hydroxymethyl group as highly potent and selective antagonists. J. Med. Chem. 2007, 50, 3159-3162.